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Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan® (ivermectin, Merck,
Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance
system required of all onchocerciasis mass treatment programs, 65 were cases of 'Probable' or
'Possible' Loa loa Encephalopathy temporally Related to treatment with Mectizan® (PLERM).
A retrospective analysis of these 65 PLERM cases revealed that 97% were from southern
Cameroon, 85% were male and 93% were being treated with ivermectin for the first time. The
mean time to onset of symptoms was 1.7 days (95% CI: 1.3, 2.2) but the mean time to receiving
medical attention after the onset of symptoms was 2.0 days (95% CI: 1.5, 2.6). Hospitalization was
reported in 53 cases with a mean duration of 27.5 days (95% CI: 13.3, 41.6, n = 35). Clinical
outcome was reported in 34 cases: 64.7% recovered fully, 11.8% had partial neurologic deficit and
23.5% died. For the 32 cases where quantitative L. loa data were reported, the arithmetic means
with 95% confidence intervals were for 1) peripheral blood: pre-treatment – 164,250 mf/ml
(79,537, 248,963; n = 4); post-treatment within 1 month – 3926 mf/ml (2,128, 5,725; n = 21) and
within 5 to 6 months – 7800 mf/ml (3417, 12,183; n = 7); and for 2) cerebrospinal fluid: 32 mf/ml
(7, 37; n = 10) within 1 month post-treatment.
Pending further research on practical methods to exclude individuals with high intensity L. loa
infection from onchocerciasis mass treatment programs, more emphasis should be placed on
surveillance and monitoring to ensure early recognition, referral and management of SAEs, during
the first 2 years when majority of the population is presumably naïve to ivermectin.
Background
The demonstration of the safety and effectiveness of Mec-
tizan® (ivermectin, Merck, Sharpe & Dohme) as a micro-
filaricidal agent against Onchocerca volvulus, and the
decision of the manufacturer, Merck & Co., Inc. in 1987,
to donate the drug to all who need it for as long as it is
needed for the treatment of onchocerciasis was of critical
importance to the control of onchocerciasis which had
previously relied primarily on vector control [1,2]. Over
the past 15 years, considerable amounts of financial,
logistical and human resources have been mobilized by
local, national and international health authorities to
implement ivermectin mass treatment programs in coun-
tries where onchocerciasis is highly endemic [3,4]. Entire
communities, in which people with onchocerciasis and/
or at high risk of the disease reside, have been treated
annually, or in some instances more frequently, with iver-
mectin since 1989.
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Serious Adverse Events (SAEs) (See Note) associated with
ivermectin treatment were found to be rare in clinical and
community trials [1,5,6]. Reports received through the
passive surveillance system, established in countries
where mass treatment with ivermectin for the control of
onchocerciasis has been operational, have provided fur-
ther confirmation of this observation. A total of 207 SAE
cases were reported from January 1989 to December
2001, giving rise to a cumulative incidence of 1 reported
SAE per 800,000 reported treatments of ivermectin [7].
These numbers are reassuring when viewed as a whole.
However, when these data are disaggregated geographi-
cally, as well as by type of clinical presentation, concern-
ing trends emerge.
Approximately 85% of the reported SAE cases originated
from Cameroon (i.e. 176 out of 207) while the remaining
31 cases were reported from neighboring countries in
Central Africa (Central African Republic, Democratic
Republic of the Congo and Sudan) as well as East Africa
(Ethiopia) and West Africa (Nigeria and Liberia) [7]. The
most common clinical presentation documented on the
SAE reports was encephalopathy following ivermectin
treatment; this represented 50% of the cases (103 out of
207) [7]. In 63% of these encephalopathic cases (65 out
of 103), there was a documented association with loiasis.
Loiasis is caused by infection with Loa loa, a filarial para-
site, and is endemic in certain regions of Central and West
Africa, the former of which has the highest prevalence and
intensity of infection [8]. The disease typically presents
with temporary localized edema (Calabar swellings), epi-
sodic subconjunctival migration of the adult worm, der-
matitis and fatigue [9]. Rarely, L. loa has been determined
to be the causative factor in spontaneous cases of enceph-
alopathy wherein the patients' cerebrospinal fluid (CSF)
and/or blood were positive for L. loa microfilariae [10]. In
a literature review by van Bogaert and colleagues, several
cases of this syndrome were described; they were mani-
fested by some of the following symptoms and signs in a
progressive or intermittent manner: rigors, hyperpyrexia,
headache, vomiting, hypertonia, confusion, agitation, tor-
por, coma, hemiplegia, aphasia, personality change, tran-
sient ocular signs and a meningeal syndrome [10]. It has
also been demonstrated that treatment with microfilari-
cidal agents such as ivermectin and diethylcarbamazine
provoke the passage of L. loa microfilariae into the CSF
and precipitate an encephalopathy similar to that seen in
spontaneous cases [10,11]. There is no definitive treat-
ment for L. loa encephalopathy; only supportive care is
recommended.
Table 1: Case definitions of encephalopathy following treatment with ivermectin*
Definite Case of Loa Encephalopathy
• Encephalopathy in which brain tissue obtained by autopsy or by needle sampling has microscopic findings consistent with L. loa encephalopathy 
(vasculopathy with evidence of L. loa microfilariae as a likely etiology), and
• Onset of Central Nervous System (CNS) symptoms and signs within 7 days of treatment with ivermectin; illness progressing to coma without 
remission.
Probable Case of Loa Encephalopathy
• Encephalopathy (without seizures, usually with fever) in a person previously healthy and has no other underlying cause for encephalopathy, and
• Onset of progressive CNS symptoms and signs within 7 days of treatment with ivermectin; illness progressing to coma without remission, and
• Peripheral blood L. loa > 10,000 mf/ml pre-treatment or > 1,000 mf/ml within 1 month post-treatment or > 2700 mf/ml within 6 months of 
treatment; and/or L. loa microfilariae present in cerebrospinal fluid (CSF) within 1 month post-treatment.
Possible Case of Loa Encephalopathy
• Encephalopathy (without seizures, usually with fever) in a person previously healthy and has no other underlying cause for encepahalopathy, and
• Onset of progressive CNS symptoms and signs within 7 days of treatment with ivermectin; illness progressing to coma without remission, and
• Semi-quantitative or non-quantitative positive (i.e. +, ++, +++) L. loa microfilariae in peripheral blood within 1 month post-treatment.
Encephalopathy of other known etiology
• Encephalopathy with sufficient clinical information to determine an etiology other than L. loa (e.g. cerebral malaria)
Encephalopathy of unknown etiology
• Encephalopathy (without seizures, usually with fever) in a person previously healthy and has no other underlying cause for encephalopathy, and
• Onset of progressive CNS symptoms and signs within 7 days of treatment with ivermectin, and
• Clinical and/or laboratory findings are inadequate to determine probable etiology.
*These definitions were adapted from those originally put forth, by a group of independent experts that consulted for the MDP in 1995 in the 
following ways: 1 the timeframe within which a case would be considered was extended from 5 to 7 days because a prospective study published in 
1997 showed that the onset of symptoms may be as late as 7 days post treatment [12]; 2 the interval between ivermectin treatment and initial L. loa 
laboratory studies was shortened to 1 month since a later study had shown that L. loa microfilarial loads decrease by 96% of pre-treatment levels 1 
month after a single standard dose of ivermectin [15]; 3 the thresholds for the quantitative L. loa laboratory studies were broadened to include 
samples taken 5 or 6 months post-treatment since several cases in Cameroon who were treated in peripheral health centers and had no laboratory 
studies performed initially, were subsequently evaluated in their villages by a team of clinicians sponsored by the national-level Ministry of Health; 
the figure of 2700 mf/ml at 6 months was derived from a calculation based on the finding that on average L. loa microfilarial loads are reduced by at 
least 73% 6 months after a single standard dose of ivermectin [19]; 4 the category of 'possible' L. loa encephalopathy was added to the list of 
presumptive diagnoses to better capture the reality of the field situation where most of the encephalopathic cases were treated in peripheral 
hospitals which were not equipped to perform lumbar punctures or quantitative L. loa microfilaremia studies until very recently.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
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Previous research on the development of L. loa encepha-
lopathy following ivermectin treatment has demonstrated
an association with 'high' levels of pre-treatment L. loa
microfilariae, with 'high' being variously described as
greater than 10,000 microfilariae per milliliter of periph-
eral blood (mf/ml) by a group of experts convened by the
Mectizan® Donation Program (MDP) in 1995 to conduct
an independent review of reported cases of probable L. loa
encephalopathy following ivermectin treatment, or
greater than 30,000 mf/ml in a hospital study in southern
Cameroon [11] or greater than 50,000 mf/ml in a com-
munity trial in southern Cameroon [12].
All encephalopathic cases temporally related to ivermec-
tin treatment occurring in onchocerciasis mass treatment
programs that have ever been reported to the MDP have
been systematically screened for documentation of infec-
tion with L. loa, and categorized according to the case def-
initions in Table 1. The categorization of the 103
encephalopathic cases reported to the MDP from January
1, 1989 to December 31, 2001 and their geographical dis-
tribution are shown in Table 2 and Figure 1 respectively.
Included in these illustrations are the 65 encephalopathic
cases which had documented infection with L. loa such
that they met the presumptive diagnosis of 'probable' or
'possible' case of L. loa encephalopathy temporally related
to ivermectin treatment as defined in Table 1. The demo-
graphic and clinical description of these 65 cases of L. loa
encephalopathy following ivermectin treatment forms the
subject of this paper. To date, the published literature on
this clinical entity has been limited to case reports and
case series of a few patients, because it occurs so rarely. To
our knowledge, this is the first paper that systematically
reviews a large number of such patients. The implications
for mass treatment strategies using ivermectin are
discussed.
Methods
A review of all SAE cases temporarily associated with iver-
mectin treatment occurring from January 1, 1989 to
December 31, 2001 that have been reported to the MDP
is published elsewhere in this series [7]. This retrospective
analysis of 'probable' and 'possible' cases of L. loa enceph-
alopathy temporally related to ivermectin treatment dur-
ing the same time period represents a subset of those
reported SAE cases. For the purposes of this analysis, the
'probable' and the 'possible' cases have been grouped
together and termed as PLERM (Probable or Possible L.
loa Encephalopathy temporally Related to treatment with
Mectizan®).
The demographic and clinical features analyzed were as
follows: age, gender, pre-existing health status, first-time
exposure to ivermectin, time interval between administra-
tion of ivermectin and onset of symptoms, time interval
from onset of symptoms to receiving medical attention,
medical management, L. loa laboratory studies and clini-
cal outcome. There were insufficient data to include an
analysis of co-infection with any other parasites.
Data were abstracted from the SAE reports and medical
records received by the MDP from onchocerciasis mass
treatment programs through a passive surveillance sys-
tem. These data were entered into a database using File-
maker Pro Version 5.0 software (Filemaker Inc., Santa
Clara, CA, USA http://www.filemaker.com/) and were
maintained by the MDP as part of its routine program
activities. The data were analyzed with the SAS System for
Windows Version 8.2 (SAS Institute, Cary, NC, USA http:/
/www.sas.com/).
Table 2: Encephalopathic cases following ivermectin treatment 
reported from onchocerciasis mass treatment programs from 
1989 to 2001*
Type of Encephalopathy† Total no. of cases
Definite L. loa encephalopathy 0
Probable L. loa encephalopathy 33
Possible L. loa encephalopathy 32
Encephalopathy of other known etiology 1‡
Encephalopathy of unknown etiology 37
Total 103
*cases reported as of August 31, 2002; †see Figure 1 for definitions of 
types of encephalopathy; ‡case of cerebral malaria.
Geographical distribution of reported encephalopathic cases  following mass treatment with ivermectin from 1989 to 2001  (as of August 31, 2002) Figure 1
Geographical distribution of reported encephalopathic cases 
following mass treatment with ivermectin from 1989 to 2001 
(as of August 31, 2002)Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
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Results
Sixty-three of the 65 reported PLERM cases (97%) were
from Cameroon. Figure 2 illustrates the frequency of
reporting of PLERM cases from 1989 to 2001. Peak report-
ing occurred in 1994 and 1999 from Central Province in
Cameroon, coincident with the expansion of ivermectin
mass treatment programs into onchocerciasis endemic
areas where the majority of the population was presuma-
bly naïve to ivermectin.
Since data were incomplete for certain variables analyzed,
the number of entries available for each result is provided
in parentheses. Eighty percent of the PLERM cases were
male (n = 65). The mean age of PLERM cases was 39.8
years (95% CI: 36.2, 43.4; n = 64). The age distribution is
shown in Table 3. Of those whose prior exposure to iver-
mectin was known (n = 44), 93% were being treated with
it for the first time. The patient's general health status
prior to taking ivermectin was reported in 38 cases, 97%
of which was documented as 'good', as opposed to 'fair' or
'poor'.
The symptoms and signs most frequently manifested by
the PLERM cases are illustrated in Table 4. Data were una-
vailable to determine the progression of symptoms over
time. The mean time to onset of symptoms after ivermec-
tin treatment was 1.7 days (95% CI: 1.3, 2.2; n = 31). Data
were insufficient to distinguish between the time to onset
of non-neurologic and neurologic symptoms. The mean
time to receive medical attention after onset of symptoms
was 2.0 days (95% CI: 1.5, 2.6; n = 53). Medical manage-
ment consisted primarily of supportive treatment: 69%
intravenous fluids, 55% corticosteroids, 43% vitamin B
complex, 26% antibiotics, 24% antipyretics, analgesics or
nonsteroidal anti-inflammatory agents, and 23% antima-
larial therapy. Fifty-three patients were reported as being
PLERM cases reported from onchocerciasis mass treatment programs from 1989 to 2001* Figure 2
PLERM cases reported from onchocerciasis mass treatment programs from 1989 to 2001* *cases reported as of August 31, 
2002; all cases were reported from southern Cameroon other than 1 from the Central African Republic in 1997 and 1 from 
southern Sudan in 2001
Table 3: Age Distribution of PLERM cases reported to have 
occurred in onchocerciasis mass treatment programs from 1989 
to 2001*
Age group (years) No. of PLERM cases† (%)
< 15 2 (3.1)
>= 15 < 30 16 (25.0)
>= 30 < 45 24 (37.5)
>= 45 < 60 17 (26.6)
>= 60 5 (7.8)
Total 64 (100)
*cases reported as of August 31, 2002; †the age of 1 case was 
unknown.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
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hospitalized; in the remaining 12 cases this was not docu-
mented. The mean duration of hospitalization was 27.5
days (95% CI: 13.3, 41.6; n = 35). Clinical outcomes were
documented in only 34 out of the 65 cases (52%); these
are shown in Table 5. In the 8 fatal cases, whom were all
hospitalized, the immediate antecedents to death were
reported in 5 of them: infected decubitus ulcers (n = 3),
systemic metabolic disorder (n = 2).
By definition, 'possible' PLERM cases (n = 33) had only
semi-quantitative or qualitative studies and thus could
not be included in a quantitative analysis. PLERM cases
which were 'probable' (n = 32) had quantitative L. loa
peripheral blood studies measured either pre-treatment or
post-treatment at varying time points in the illness and/or
quantitative or qualitative L. loa studies of the CSF. Since
the exact temporal relationship with ivermectin treatment
was not always recorded, the post-treatment L. loa labora-
tory data were grouped into 2 broad categories: 1) within
1 month post-treatment; and 2) at subsequent follow-up
5 to 6 months after treatment. These data are shown for
the 32 'probable' cases in Table 6.
Discussion
This retrospective analysis of 65 reported PLERM cases
from onchocerciasis mass treatment programs (97% of
which were from Cameroon) has shown that the majority
of cases were male. Peak reporting occurred in years when
onchocerciasis mass treatment programs were expanded
to areas where the population was generally naïve to iver-
mectin; this is consistent with the finding that over 90%
of PLERM cases reported first exposure to ivermectin. The
mean age of PLERM cases was about 40 years and more
than one-third of the cases were between the ages of 30
and 44 years. Symptoms and signs generally developed
within 2 days but there was a delay of an additional 2 days
before the patient received medical attention. Supportive
care was the mainstay of medical management. Most
patients were hospitalized for about a month. Clinical
outcome was reported in only 53% of cases; of these the
majority recovered fully while about a quarter of them
died. The arithmetic mean L. loa micofilarial load within
1 month post-treatment was approximately 4000 mf/ml.
The limitations of this dataset need to be explicitly stated
in order to place these results in their appropriate context.
First, there were substantial amounts of data missing,
almost 50% for some of the variables analyzed. To some
extent, this reflects the evolution of the SAE reporting
form during the time period under review. 1) The SAE
reporting form has been revised 3 or 4 times during the 13
years under review. Thus, the data received from the field
differed in the depth of detail that was documented over
the years. In particular, a specific question of L. loa infec-
tion was not included on the form until 1997 although
there was always room to report whatever information the
clinician believed to be relevant even if it was not
specifically requested on the form. 2) The SAE reporting
form (both previous and current versions) requested clini-
cians to primarily write free text as opposed to choose one
out of a range of options. This system provided for rich-
ness of data on the one hand, but constrained standardi-
zation of data for the purposes of statistical analysis, on
the other hand. Even when check boxes were provided
they were sometimes left blank.
Second, determination of the extent to which the true
number of PLERM cases has been reported is limited
because almost all the PLERM cases analyzed in this paper
were reported spontaneously in a passive, rather than
active, surveillance system. A passive surveillance system
such as this depends on four key factors: 1) the awareness
of clinicians at all levels of the health care system to make
a temporal association between the clinical condition and
antecedent ivermectin treatment; 2) clinician knowledge
Table 4: Frequency of clinical signs and symptoms of PLERM 
cases reported to have occurred in onchocerciasis mass 
treatment programs from 1989 to 2001*
Clinical sign or symptom Frequency of occurrence (%)
Altered mental status 65 (100)
- confusion, obtundation or 
lethargy
- 31 (47.7)
- stupor - 13 (20.0)
- coma - 21 (32.3)
Incontinence (urinary & fecal) 28 (43.1)
Difficulty standing up or walking 25 (38.5)
Dysarthria or aphasia 21 (32.3)
Fever (documented) 19 (29.2)
Diarrhea 16 (24.6)
Headache 15 (23.1)
Low back pain 10 (15.4)
Feverishness or chills 10 (15.4)
*cases reported as of August 31, 2002.
Table 5: Clinical outcome of PLERM cases reported to have 
occurred in onchocerciasis mass treatment programs from 1989 
to 2001*
Reported clinical outcome Frequency of occurrence† (%)
Full recovery 22 (64.7)
Partial neurologic deficit 4 (11.8)
Death 8 (23.5)
Total 34 (100)
*cases reported as of August 31, 2002; †clinical outcome of 31 cases 
unknown.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
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of the typical and atypical adverse events temporally asso-
ciated with ivermectin treatment; 3) the extent to which
diagnostic tests were performed in an appropriate and
timely manner; and 4) the integrity of the adverse drug
reaction reporting system for ivermectin (and other phar-
maceuticals in general) from peripheral levels to a central
health authority in-country and finally to the MDP. Given
the variability of reporting from the 34 onchocerciasis-
endemic countries that have had, or have, ivermectin
mass treatment programs, it is unknown what the true
numbers of SAE cases in general, and PLERM cases in par-
ticular, are. Finally, since 37 of the reported 103 encepha-
lopathic cases had insufficient clinical and laboratory
information documented to determine a presumptive
etiology (see Table 2), it is probable that the number of
PLERM cases has been underestimated in this analysis
especially as most of them were also reported from L. loa
endemic areas of southern Cameroon.
Notwithstanding the stated limitations, the major find-
ings from this analysis are worthy of some discussion.
First, the observation that more than one-third of the
reported PLERM cases were between the ages of 30 and 44
is consistent with a previously published community trial
which showed that individuals within this age group are
at greatest risk of developing SAEs [12]. However in that
study neurologic, and non-neurologic SAEs were com-
bined for the analysis. Second, the finding that males con-
stituted 85% of the reported PLERM cases is striking. Of
note, 85% of the published case reports on PLERM (i.e. 11
out of 13) have also been male [13,14]. Whether this rep-
resents a true gender distribution of disease is unknown
since these studies, including the present one, were not
designed to test this hypothesis. Further research investi-
gating gender differences in the exposure to Chrysops spp.
(the vector of L. loa), L. loa microfilarial intensity, suscep-
tibility to L. loa encephalopathy following ivermectin
treatment independent of the intensity of L. loa infection,
health-seeking behaviors or other such factors may pro-
vide some insight into this question.
Third, the observation that 93% of cases were being
treated with ivermectin for the first time is important bio-
logically as well as programmatically. Since ivermectin
kills the microfilariae of both O. volvulus and L. loa [1],
and the rapid destruction of a large burden of L. loa micro-
filariae has been temporally related to L. loa encephalop-
athy following ivermectin treatment [13], and L. loa
microfilarial loads have been shown to decrease by 96%
after 1 month of single-dose treatment [15], this result is
consistent with the putative pathogenesis of L. loa enceph-
alopathy following ivermectin treatment. Furthermore,
from a programmatic perspective, this could have sub-
stantial implications on the human and financial
resources needed for mass treatment programs in L. loa
endemic areas. Field personnel in these areas could limit
the intensive training and surveillance for the manage-
ment of SAEs to the first 2 years of the program when the
majority of the population is expected to be naïve to iver-
mectin, if high treatment coverage is attained initially and
maintained over time.
Fourth, symptoms and signs (non-neurologic and/or neu-
rologic) of the adverse drug event generally began within
the first 48 hours of treatment; this is consistent with pub-
lished clinical case reports [13,14]. In the present study,
data were insufficient to distinguish between the onset of
non-neurologic and neurologic symptoms. However, Gar-
don and colleagues have argued that the clinical sequelae
following ivermectin treatment in people with high L. loa
microfilarial loads represent a continuum with the follow
stages: "mild", "marked", "serious non-neurologic" and
"serious neurologic" [12]. In their prospective study dur-
ing which 2 PLERM cases occurred, alteration of con-
sciousness began 3–4 days after ivermectin treatment.
Thus, it may be useful for field programs in L. loa endemic
areas to further intensify their surveillance activities dur-
ing the first 4 days following mass treatment.
Interpretation of the data on L. loa microfilaremia is lim-
ited since about half of the cases met the definition of
PLERM due to qualitative or semi-quantitative data (i.e.
Table 6: Loa loa quantitative laboratory studies available for 'probable' PLERM cases reported to have occurred in onchocerciasis mass 
treatment programs from 1989 to 2001, n = 32*
Peripheral blood Cerebrospinal fluid
Pre-treatment (mf/ml) Within 1 mth post-
treatment (mf/ml)
Within 5–6 mths post-
treatment (mf/ml)
Within 1 mth post-
treatment (mf/ml)
Number of cases with 
available data
42 071 0
Arithmetic mean (95% 
CI)
164,250 (112,078; 216,422) 4114 (2380; 5,848) 7800 (3,417; 12,183) 32 (7; 57)
*cases reported as of August 31, 2002.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
Page 7 of 8
(page number not for citation purposes)
the 'Possible' cases'). However for the 20 cases where post-
treatment microfilaremia levels were available within 1
month of treatment, the arithmetic mean value of 4000
mf/ml suggests that pre-treatment levels were probably
much higher than 10,000 mf/ml, the risk threshold pro-
posed by the first independent consultation of experts on
this clinical entity and perhaps closer to 100,000 mf/ml if
one estimates a 96% reduction in pre-treatment levels
after 1 month as demonstrated by Kombila and colleagues
[15]. Given the inter-individual variability in the decline
of L. loa microfilarial loads after treatment and the rather
wide interval of 1 month used in this study, further
research is required to re-assess the rate of decline of L. loa
microfilaremia within 1 week of treatment with
ivermectin since that is the time frame within which most
patients present for medical care.
There were insufficient data to analyze the potential role
of co-infection with Plasmodium falciparum or other para-
sites that sometimes manifest as encephalopathic illnesses
which could either increase susceptibility to the develop-
ment of L. loa encephalopathy following ivermectin treat-
ment or serve as confounding factors in this analysis.
In summary, SAEs following ivermectin administration in
onchocerciasis mass treatment programs are very rare: 1
reported case per 800,000 treatments from the passive sur-
veillance system of the MDP. Overall, reported PLERM
cases are also quite rare even in Cameroon, as demon-
strated in a prospective study conducted in southern Cam-
eroon – which showed an incidence of PLERM of
approximately 1 per 10,000 treatments administered in
an onchocerciasis mass treatment program [12]. How-
ever, the incidence of PLERM appears to vary considerably
within  L. loa endemic areas [16]. Further research is
needed to investigate possible geographic differences in
the genetics of the human host, and/or the strain of L. loa
and/or the Chrysops vector, and/or other environmental
putative etiologic factors that increase the vulnerability of
populations in some parts of southern Cameroon to
developing  L. loa encephalopathy following treatment
with ivermectin.
The current strategies for onchocerciasis mass treatment
programs using ivermectin emphasize community rather
than individual assessment of the risk of onchocerciasis.
Since 2000, the Mectizan® Expert Committee has recom-
mended additional measures for onchocerciasis mass
treatment areas where loiasis is co-endemic that aim to
refine community risk of onchocerciasis at the village-by-
village level rather than on a sampling framework, and
increase the health education and awareness needed for
SAE surveillance, referral and management. Recent inves-
tigation of a rapid epidemiologic technique for identify-
ing communities with a high likelihood of having
individuals at high risk of L. loa encephalopathy following
ivermectin treatment based on the prevalence of the his-
tory of subconjunctival migration of the L. loa adult worm
[17], is very encouraging. Once this technique is validated
it could be applied in the field to exclude high-risk com-
munities from onchocerciasis mass treatment programs
with ivermectin or to identify communities where further
enhancement of SAE surveillance and management is
required if the risk of onchocercal blindness and skin dis-
ease is deemed to outweigh the risk of L. loa encephalop-
athy following ivermectin treatment such that mass
treatment with ivermectin is believed to be indicated.
However, there is currently no simple diagnostic tool with
high specificity and sensitivity that can be easily applied
under field conditions to exclude individuals at high risk
for L. loa encephalopathy following ivermectin treatment;
a consensus on the minimum L. loa microfilaremia risk
level would need to be reached in order to ensure maxi-
mum effectiveness of the tool. Even if a risk threshold was
reliably defined, collecting blood smears on all individu-
als eligible for mass treatment for parasitological assess-
ment, with its requirement of skilled technicians and
attendant risk of transmission of blood-borne infections,
is not suitable for mass treatment programs. Thus, there is
an urgent need for a non-invasive, rapid assessment tool
that is highly sensitive and specific and can be reliably
used by lay health workers who are most often the distrib-
utors of ivermectin at the community level.
This tool, if developed, would also be of great importance
to the Global Programme to Eliminate Lymphatic Filaria-
sis (GPELF) since it too depends on mass treatment with
ivermectin. In areas co-endemic for onchocerciasis and
lymphatic filariasis (LF), the World Health Organization
recommends annual mass co-administration of
ivermectin and albendazole (donated by GlaxoSmithK-
line) [18] except for in L. loa endemic areas where the risk
benefit assessment of mass treatment with this combina-
tion of drugs for the interruption of LF transmission as
opposed to the treatment of LF disease, has weighed heav-
ily against mass treatment since the launch of the GPELF
in 1999 pending further safety research and monitoring. A
screening tool for determining the risk of L. loa encepha-
lopathy following ivermectin treatment on an individual
level may facilitate the safe expansion of the GPELF into
the L. loa endemic areas of Central and West Africa since
global elimination of LF cannot be achieved using the cur-
rently recommended strategies if these areas continue to
be excluded from mass treatment.
In the absence of an individual screening tool, onchocer-
ciasis mass treatment programs must continue to
emphasize surveillance, monitoring, early detection,
referral and management of SAE cases. The findings from
this analysis could provide guidance in focusing theFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S7
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increased surveillance efforts on individuals at greatest
risk of developing L. loa encephalopathy following iver-
mectin treatment during the first 4 days following mass
treatment with ivermectin in the first 2 years of onchocer-
ciasis mass treatment programs in L. loa endemic areas if
high treatment coverage can be achieved initially and
maintained over time.
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Note
A Serious Adverse Experience is defined as follows:
"an adverse experience following treatment with a drug
that results in any of the following:
• death
• life-threatening adverse drug experience
• in-patient hospitalization or prolongation of an existing
hospitalization
• persistent or significant disability/incapacity
• congenital anomaly or birth defect
• cancer
• overdose (accidental or intentional).
Important medical events that may not result in death, be
life-threatening, or require hospitalization may be consid-
ered a serious adverse drug experience when, based upon
appropriate medical judgment, they may jeopardize the
patient or subject, and may require medical or surgical
intervention to prevent one of the outcomes listed in the
definition above: such events should also be reported."
(Merck & Co., Inc., adapted from the definitions of the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use)
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